Overview

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

Status:
Not yet recruiting
Trial end date:
2022-12-03
Target enrollment:
Participant gender:
Summary
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-386 in healthy volunteers under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical